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For the past 30 years levodopa (LD) has been the phar-
macological standard of care for treating idiopathic Par-
kinson’s disease (PD), a neurodegenerative disease of the
central nervous system. LD is a pharmacologically inac-
tive precursor, which is converted enzymatically to the
neurotransmitter dopamine by a declining population of
neurons in the substantia nigra, the most important site
of the pathology of PD. Most patients experience a
smooth, lasting response to small amounts of LD during
the early years of treatment, but as the underlying dis-
ease gets worse, treatment-related problems arise.
Motor fluctuations, which slowly emerge after 3–5 years
of chronic LD therapy, gradually replace the smooth
pattern of response, and more frequent dosing is
required. Abnormal involuntary movements (dyskinesia),
wearing-off of the motor response after a few hours,
organic psychosis (confusion and hallucinations), and
progressive loss of independence characterize the com-
plication of the pharmacological treatment of PD.
Despite its problems and the recent development of
other antiparkinson drugs, LD remains the most effec-
tive pharmacologic agent available for the relief of symp-
toms in patients with PD. The use of dopamine agonists
has been greatly encouraged in recent years. The main
indication for their use is the initial therapy of patients
with PD, particularly in younger patients. Several studies
have reported that their early use may delay the onset of
motor fluctuations and dyskinesia. The principal dopa-
mine agonists are ergoline (bromocriptine, lisuride, per-
golide, cabergoline) and non-ergoline (ropirinolo and
pramipexole).
Apomorphine is a drug with a pharmacological profile
comparable to that of dopamine. When administered
subcutaneously in subjects with PD, apomorphine is
able to quickly reverse the periods of motor off. It is
therefore used in cases with severe motor fluctuations,
either by continuous infusion via a portable micropump
with or by single bolus injections.
MAO and COMT are enzymes that metabolize dopa-
mine in the central nervous system. Inhibitors of MAO
and COMT are used to prolong the half-life of LD.
Such drugs are represented by selegiline (MAO inhibi-
tor) and tolcapone and entacapone (COMT inhibitors).
The Italian guidelines suggest different treatment strate-
gies according to the age of the patients with PD: for
patients with early onset (<50 years) monotherapy is
recommended with dopamine agonists that may be
associated with a low dose of LD; for patients aged 50
to 70 years monotherapy is recommended with dopa-
mine agonists or with LD or association between the
two treatments.
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